Navigation Links
Nerites Receives NIH Grant to Study Novel Treatment for Preventing Dangerous Bacterial Infections on Urinary Stents and Catheters
Date:1/21/2008

MADISON, Wis., Jan. 21 /PRNewswire/ -- While urinary stents and catheters can be life-saving medical devices, 40 percent of patients end up with bacterial infections. With 100 million placed in patients each year, this means that doctors must treat 40 million device-associated infections annually. Nerites Corporation is testing its unique new technology for preventing these dangerous infections, with funding from a $100,000 small business innovation research grant (SBIR) from the National Institute of Diabetes and Digestive and Kidney Diseases at the National Institutes of Health (NIH).

The study will determine whether Nerites novel polymer coatings can prevent biofilm growth, the source of most infections on urinary stents and catheters. Biofilms grow on the surface of the device and provide an anchor for bacteria, which then recruit other bacteria and cause infection.

"Current methods to prevent biofilms are expensive, often ineffective and can promote antibiotic resistance," said Thomas J. Mozer, Ph.D., CEO and President of Nerites Corporation. "This money will help us test our coating technology, which we believe will block biofilm formation reliably and inexpensively, without antibiotics or biocides."

About Nerites: Nerites Corporation develops novel tissue repair products as well as advanced coatings for implanted medical devices and device uses on skin based on unique "wet" adhesive compounds. These synthetic compounds are based upon research by Dr. Phil Messersmith at Northwestern University's Department of Biomedical Engineering on how marine mussels bind to surfaces underwater, are a breakthrough advance in biologically-compatible adhesives that provide completely new options for tissue repair, skin adhesives, and device coatings. Nerites is based in Madison Wisconsin. (http://www.nerites.com)


'/>"/>
SOURCE Nerites Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes
2. MultiVu Video Feed: WELCHOL (R) (COLESEVELAM HCL) RECEIVES FDA APPROVAL FOR GLUCOSE CONTROL IN ADULTS WITH TYPE 2 DIABETES MELITUS
3. Novadaqs SPY System receives clearance for use in organ transplant surgery
4. BeneChills RhinoChill System Receives CE Marking for European Commercial Sale
5. e-Health Card Terminal From SCM Microsystems Receives GEMATIK Certification
6. Breckenridge Pharmaceutical Settles Paragraph IV Litigation and Receives FDA Approval for its Oxcarbazepine ANDA
7. LifeMasters Receives Full URAC Disease Management Accreditation
8. Federal Government Receives Failing Grades on Tobacco Control in Annual American Lung Association Report
9. Glory Foods Receives Heart Healthy Certification
10. TeamStaff Receives Nasdaq Determination Letter
11. Gary Tschautscher of Nonin Medical, Inc. Receives CEO of 2007 for North American Patient Monitoring From Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to ... of individuals in the United States and Canada wear eyeglasses. Once considered to be ... vision and make a fashion statement. Even celebrities use glasses as a way of ...
(Date:6/26/2016)... Viejo, California (PRWEB) , ... June 26, 2016 , ... ... Final Cut Pro X. , "Film editors can give their videos a whole new ... said Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels contains ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women ... diagnosed with endometriosis. These women need a treatment plan to not only alleviate ... that can help for preservation of fertility and ultimately achieving a pregnancy. The ...
(Date:6/25/2016)... ... ... The temporary closing of Bruton Memorial Library on June 21 due to a possible lice ... overlooked aspect of head lice: the parasite’s ability to live away from a human host, ... a necessary one in the event that lice have simply gotten out of control. , ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... RIDGE, Ill. and INDIANAPOLIS ... of students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship ... The 2016 scholarship winners, announced today online at ... to let type 1 diabetes stand in the way ... Diabetes has supported the Foundation,s scholarship program since 2012, ...
(Date:6/23/2016)... 2016 The vast majority of dialysis patients ... Treatments are usually 3 times a week, with treatment ... travel time, equipment preparation and wait time.  This regimen ... for patients who are elderly and frail.  Many elderly ... rehabilitation centers for some duration of time. ...
Breaking Medicine Technology: